Radnor Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Radnor Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.57M	Sell	79,233 -465	-0.6%	-$26.7K	0.64%	30
2026 Q1	$4.83M	Buy	79,698 +1,340	+2%	+$78.1K	0.72%	28
2025 Q4	$4.23M	Buy	78,358 +1,785	+2%	+$85.9K	0.63%	32
2025 Q3	$3.45M	Sell	76,573 -5,368	-7%	-$251K	0.53%	46
2025 Q2	$3.79M	Buy	81,941 +1,150	+1%	+$56.5K	0.61%	38
2025 Q1	$4.93M	Sell	80,791 -75	-0.1%	-$4.37K	0.83%	23
2024 Q4	$4.57M	Sell	80,866 -8,600	-10%	-$481K	0.76%	22
2024 Q3	$4.63M	Buy	+89,466	New	+$4.2M	0.69%	29
2024 Q2	–	Sell	-66,823	Closed	-$3.62M	–	169
2024 Q1	$3.62M	Sell	66,823 -169	-0.3%	-$8.61K	0.62%	35
2023 Q4	$3.44M	Sell	66,992 -2,914	-4%	-$153K	0.64%	30
2023 Q3	$4.06M	Buy	+69,906	New	+$4.28M	0.81%	22
2023 Q2	–	Sell	-54,866	Closed	-$3.8M	–	145
2023 Q1	$3.8M	Buy	54,866 +2,780	+5%	+$196K	1%	17
2022 Q4	$4.03M	Sell	52,086 -35	-0.1%	-$2.64K	0.99%	15
2022 Q3	$3.71M	Sell	52,121 -40	-0.1%	-$2.9K	1.07%	14
2022 Q2	$4.02M	Buy	52,161 +2,275	+5%	+$173K	1.1%	15
2022 Q1	$3.64M	Sell	49,886 -30	-0.1%	-$2.01K	0.91%	19
2021 Q4	$3.11M	Buy	+49,916	New	+$2.93M	0.77%	26
2021 Q3	–	Sell	-47,716	Closed	-$3.19M	–	114
2021 Q2	$3.19M	Buy	47,716 +155	+0.3%	+$10.1K	1.08%	18
2021 Q1	$3M	Buy	47,561 +2,825	+6%	+$176K	0.97%	21
2020 Q4	$2.77M	Buy	44,736 +580	+1%	+$35.7K	0.78%	25
2020 Q3	$2.66M	Sell	44,156 -1,000	-2%	-$60.2K	0.89%	25
2020 Q2	$2.68M	Buy	45,156 +644	+1%	+$38.5K	0.97%	22
2020 Q1	$2.48M	Sell	44,512 -382	-0.9%	-$23.3K	1.02%	22
2019 Q4	$2.88M	Hold	44,894	–	–	0.89%	26
2019 Q3	$2.28M	Buy	44,894 +700	+2%	+$32.9K	0.75%	29
2019 Q2	$2M	Buy	44,194 +3,475	+9%	+$162K	0.66%	34
2019 Q1	$1.94M	Buy	40,719 +1,925	+5%	+$95.9K	0.64%	34
2018 Q4	$2.02M	Buy	38,794 +1,000	+3%	+$53.7K	0.73%	28
2018 Q3	$2.35M	Buy	37,794 +3,200	+9%	+$190K	0.75%	28
2018 Q2	$1.91M	Sell	34,594 -1,700	-5%	-$91.8K	0.71%	34
2018 Q1	$2.3M	Sell	36,294 -300	-0.8%	-$19.3K	0.78%	28
2017 Q4	$2.24M	Hold	36,594	–	–	0.72%	33
2017 Q3	$2.04M	Hold	36,594	–	–	0.69%	34
2017 Q2	$2.04M	Hold	36,594	–	–	0.69%	34
2017 Q1	$1.99M	Buy	36,594 +1,150	+3%	+$63.1K	0.67%	34
2016 Q4	$2.07M	Buy	+35,444	New	+$1.94M	0.71%	29

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Radnor Capital Management's BMY Position: Q2 2026 in Review

Radnor Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.58% in Q2 2026, selling an estimated $26.7K and leaving 79,233 shares worth $4.57M. The position accounts for 0.64% of the portfolio, ranked #30.

Radnor Capital Management first reported a position in BMY in Q4 2016 and has held it in 36 quarters since. The position peaked at $4.93M in Q1 2025. 834 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Radnor Capital Management held 79,233 shares of Bristol-Myers Squibb worth $4.57M as of Q2 2026.
Radnor Capital Management sold 465 Bristol-Myers Squibb shares in Q2 2026, an estimated $26.7K.
Bristol-Myers Squibb made up 0.64% of Radnor Capital Management's portfolio in Q2 2026, its #30 holding.
Radnor Capital Management first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 36 quarters since.
Radnor Capital Management's Bristol-Myers Squibb position peaked at $4.93M in Q1 2025.
834 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Radnor Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.